Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Global Harmonization Task Force Meeting In Brief

This article was originally published in The Gray Sheet

Executive Summary

Asian Harmonization: Members of the Asian Harmonization Working Party, whose 16 economies include China, Indonesia and Korea and will soon include India, have agreed that if a product is approved after submission of one common government dossier, it will receive approval in other member countries, said Mukundan Sugundan Pillay, AHWP chair and deputy director general of health, research and technical support in the Malaysian Ministry of Health, Oct. 3 at the Global Harmonization Task Force conference in Washington, D.C. "We are also working on the principle of not reinventing the wheel, because if FDA has spent so much money evaluating a device, I'm not going to look at it - I'll approve it in 24 hours," he added

You may also be interested in...

Global Harmonization Task Force Moves Into “Implementation Mode”

Efforts to harmonize device regulations globally will see more activity over the next year if Larry Kessler has his way

IPO Year In Review: Record-Year Bodes Well For 2021, And For More SPACs

Biopharma was an attractive investment in 2020 and fundamentals are unchanged in 2021, including the pandemic’s work-at-home requirements, which allowed more companies to go public faster.

Abbott Capitalizes On Pandemic Testing Boom; Device Sales Stay Almost Flat

Abbott reported almost 28% revenue growth in the fourth quarter led by the exploding demand for COVID-19 tests and continued success of its FreeStyle Libre continuous glucose monitor.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts